Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones
Tóm tắt
Prevention of recurrent calcium stone disease includes treatment with thiazide and thiazide-type diuretics to reduce urinary calcium (UCa) levels, with the reduction in UCa correlating with risk of stone recurrence. There has been a recent trend of using lower doses of these medications and change from chlorthalidone (CTL) use to hydrochlorothiazide (HCTZ) use. It is unknown whether low doses of HCTZ are effective in lowering UCa levels to target levels. We hypothesize that HCTZ is associated with less reduction in UCa than is CTL when comparing currently used doses. Retrospective observational study of stone-formers was seen in metabolic stone clinic during a 3 years period. Data included patient demographics, co-morbidities, and 24 h urine electrolyte composition. Primary outcome was the change in 24 h UCa. 322 patients were identified with 112 meeting criteria and used in analysis. The majority were placed on HCTZ (n = 42) or CTL (n = 47) 25 mg QD. Patients on CTL 25 mg had a greater reduction in UCa (164 mg; 41 %) than those on HCTZ (85 mg; 21 %), p = 0.01. Neither CTL nor HCTZ at 12.5 mg QD significantly lowered UCa. There was a decrease in serum [K] of 0.5 Meq/L (p = 0.001) in patients on CTL 25 mg daily, but no significant difference in severe hypokalemia or arrhythmia compared to HCTZ. Our data show that CTL is associated with greater reduction in 24 h UCa compared to similarly dosed HCTZ.
Tài liệu tham khảo
Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63(5):1817–1823. doi:10.1046/j.1523-1755.2003.00917.x
Scales CD Jr, Smith AC, Hanley JM, Saigal CS (2012) Prevalence of kidney stones in the United States. Eur Urol 62(1):160–165. doi:10.1016/j.eururo.2012.03.052
Pearle MS, Calhoun EA, Curhan GC (2005) Urologic diseases in America project: urolithiasis. J Urol 173(3):848–857. doi:10.1097/01.ju.0000152082.14384.d7
Semins MJ, Matlaga BR (2010) Medical evaluation and management of urolithiasis. Ther Adv Urol 2(1):3–9. doi:10.1177/1756287210369121
Uribarri J, Oh MS, Carroll HJ (1989) The first kidney stone. Ann Intern Med 111(12):1006–1009
Rule AD, Krambeck AE, Lieske JC (2011) Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol 6(8):2069–2075. doi:10.2215/CJN.10651110
Rule AD, Roger VL, Melton LJ 3rd, Bergstralh EJ, Li X, Peyser PA, Krambeck AE, Lieske JC (2010) Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol 21(10):1641–1644. doi:10.1681/ASN.2010030253
Yendt ER, Guay GF, Garcia DA (1970) The use of thiazides in the prevention of renal calculi. Can Med Assoc J 102(6):614–620
Laerum E, Larsen S (1984) Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 215(4):383–389
Ettinger B, Citron JT, Livermore B, Dolman LI (1988) Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139(4):679–684
Fernandez-Rodriguez A, Arrabal-Martin M, Garcia-Ruiz MJ, Arrabal-Polo MA, Pichardo-Pichardo S, Zuluaga-Gomez A (2006) The role of thiazides in the prophylaxis of recurrent calcium lithiasis. Actas Urol Esp 30(3):305–309
Reilly RF, Peixoto AJ, Desir GV (2010) The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol 5(10):1893–1903. doi:10.2215/CJN.04670510
Vigen R, Weideman RA, Reilly RF (2011) Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol 43(3):813–819. doi:10.1007/s11255-010-9824-6
ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283 (15):1967–1975
Flack JM, Cushman WC (1996) Evidence for the efficacy of low-dose diuretic monotherapy. Am J Med 101(3):53S–60S
Flöge J, Johnson RJ, Feehally J (2010) Comprehensive clinical nephrology. Saunders Elsevier, St. Louis
Curhan GC, Taylor EN (2008) 24-h uric acid excretion and the risk of kidney stones. Kidney Int 73(4):489–496. doi:10.1038/sj.ki.5002708
Yendt ER, Cohanim M (1978) Prevention of calcium stones with thiazides. Kidney Int 13(5):397–409
Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR (2006) Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47(3):352–358. doi:10.1161/01.HYP.0000203309.07140.d3
Ernst ME, Carter BL, Zheng S, Grimm RH Jr (2010) Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens 23(4):440–446. doi:10.1038/ajh.2010.1
Carter BL, Ernst ME, Cohen JD (2004) Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 43(1):4–9. doi:10.1161/01.HYP.0000103632.19915.0E
SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (24):3255–3264
Sumiye L, Vivian AS, Frisof KB, Podany EC (1981) Potassium loss associated with hydrochlorothiazide versus chlorthalidone. Clin Ther 4(4):308–320
Dhalla IA, Gomes T, Zhan Y, Nagge J, Persaud N, Hellings C, Mamdami MM, Juurlink DN (2013) Chlorthalidone versus hydrochlorothiazide for treatment of hypertension in older adults. Ann Intern Med 158(6):447–455
Zuckerman JM, Assimos DG (2009) Hypocitraturia: pathophysiology and medical management. Rev urol 11(3):134–144